These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10826962)

  • 1. Nucleophilic proteolytic antibodies.
    Gololobov G; Tramontano A; Paul S
    Appl Biochem Biotechnol; 2000; 83(1-3):221-31; discussion 231-2, 297-313. PubMed ID: 10826962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate antibody catalysis.
    Gololobov G; Sun M; Paul S
    Mol Immunol; 1999 Dec; 36(18):1215-22. PubMed ID: 10684961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for immunotherapeutic proteolytic antibodies.
    Zhou YX; Karle S; Taguchi H; Planque S; Nishiyama Y; Paul S
    J Immunol Methods; 2002 Nov; 269(1-2):257-68. PubMed ID: 12379366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a serine protease-like catalytic triad on an antibody light chain displayed on the yeast cell surface.
    Okochi N; Kato-Murai M; Kadonosono T; Ueda M
    Appl Microbiol Biotechnol; 2007 Dec; 77(3):597-603. PubMed ID: 17899065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positional ordering of reacting groups contributes significantly to the efficiency of proton transfer at an antibody active site.
    Seebeck FP; Hilvert D
    J Am Chem Soc; 2005 Feb; 127(4):1307-12. PubMed ID: 15669871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural catalytic antibodies.
    Paul S
    Mol Biotechnol; 1996 Jun; 5(3):197-207. PubMed ID: 8837026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From molecular diversity to catalysis: lessons from the immune system.
    Schultz PG; Lerner RA
    Science; 1995 Sep; 269(5232):1835-42. PubMed ID: 7569920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed mutagenesis of proteolytic antibody light chain.
    Gao QS; Sun M; Rees AR; Paul S
    J Mol Biol; 1995 Nov; 253(5):658-64. PubMed ID: 7473741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies as defensive enzymes.
    Paul S; Nishiyama Y; Planque S; Karle S; Taguchi H; Hanson C; Weksler ME
    Springer Semin Immunopathol; 2005 Mar; 26(4):485-503. PubMed ID: 15633014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of a catalytic antibody with a serine protease active site.
    Zhou GW; Guo J; Huang W; Fletterick RJ; Scanlan TS
    Science; 1994 Aug; 265(5175):1059-64. PubMed ID: 8066444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The elicitation of carboxylesterase activity in antibodies by reactive immunization with labile organophosphorus antigens: a role for flexibility.
    Schowen RL
    J Immunol Methods; 2002 Nov; 269(1-2):59-65. PubMed ID: 12379352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus: molecular cloning and analysis of recombinant monoclonal kappa light chain NGTA2-Me-pro-ChTr possessing two different activities-trypsin-like and metalloprotease.
    Timofeeva AM; Ivanisenko NV; Buneva VN; Nevinsky GA
    Int Immunol; 2015 Dec; 27(12):633-45. PubMed ID: 26174315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the importance of second sphere residues in an esterolytic antibody by phage display.
    Arkin MR; Wells JA
    J Mol Biol; 1998 Dec; 284(4):1083-94. PubMed ID: 9837728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro abzyme evolution to optimize antibody recognition for catalysis.
    Takahashi N; Kakinuma H; Liu L; Nishi Y; Fujii I
    Nat Biotechnol; 2001 Jun; 19(6):563-7. PubMed ID: 11385462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completing the circle.
    Schultz PG; Lerner RA
    Nature; 2002 Aug; 418(6897):485. PubMed ID: 12152057
    [No Abstract]   [Full Text] [Related]  

  • 17. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding.
    Baca M; Scanlan TS; Stephenson RC; Wells JA
    Proc Natl Acad Sci U S A; 1997 Sep; 94(19):10063-8. PubMed ID: 9294163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition state docking: a probe for noncovalent catalysis in biological systems. Application to antibody-catalyzed ester hydrolysis.
    Tantillo DJ; Houk KN
    J Comput Chem; 2002 Jan; 23(1):84-95. PubMed ID: 11913392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural diversity of antibody catalysts.
    Golinelli-Pimpaneau B
    J Immunol Methods; 2002 Nov; 269(1-2):157-71. PubMed ID: 12379360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Just a near attack conformer for catalysis (chorismate to prephenate rearrangements in water, antibody, enzymes, and their mutants).
    Hur S; Bruice TC
    J Am Chem Soc; 2003 Sep; 125(35):10540-2. PubMed ID: 12940735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.